MBM Wealth Consultants LLC Acquires 729 Shares of Pfizer Inc. (NYSE:PFE)

MBM Wealth Consultants LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 8.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 9,347 shares of the biopharmaceutical company’s stock after acquiring an additional 729 shares during the quarter. MBM Wealth Consultants LLC’s holdings in Pfizer were worth $249,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Missouri Trust & Investment Co boosted its stake in Pfizer by 3.6% during the fourth quarter. Missouri Trust & Investment Co now owns 51,757 shares of the biopharmaceutical company’s stock worth $1,373,000 after acquiring an additional 1,801 shares in the last quarter. Bourgeon Capital Management LLC raised its holdings in shares of Pfizer by 610.3% during the fourth quarter. Bourgeon Capital Management LLC now owns 418,658 shares of the biopharmaceutical company’s stock valued at $11,107,000 after purchasing an additional 359,721 shares during the period. Octavia Wealth Advisors LLC boosted its position in shares of Pfizer by 49.3% during the 4th quarter. Octavia Wealth Advisors LLC now owns 22,159 shares of the biopharmaceutical company’s stock worth $588,000 after purchasing an additional 7,319 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its stake in shares of Pfizer by 1.4% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,629,388 shares of the biopharmaceutical company’s stock valued at $43,228,000 after buying an additional 22,562 shares during the period. Finally, JBGlobal.com LLC acquired a new position in Pfizer during the 4th quarter worth approximately $362,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Up 1.2 %

Pfizer stock opened at $26.63 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $150.89 billion, a P/E ratio of 35.98, a P/E/G ratio of 0.63 and a beta of 0.64. The firm has a 50 day moving average price of $26.08 and a 200-day moving average price of $27.98. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the prior year, the company earned ($0.17) EPS. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. As a group, equities analysts predict that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.46%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is presently 227.03%.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research reports. Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Sanford C. Bernstein initiated coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. UBS Group decreased their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Citigroup initiated coverage on shares of Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target on the stock. Finally, Wolfe Research assumed coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Insider Buying and Selling

In related news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 0.06% of the stock is owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.